EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis

Jingjing Wu, Dipti Athavale, Curt Balch, Junsong Zhao, Gengyi Zou, Yibo Fan, Yanting Zhang, Joseph Zhao, Mikel Ghelfi, Anthony Pompetti, Gennaro Calendo, Ailing Scott und 13 weitere

Cancer Heterogeneity and Plasticity · 28.03.2026

DOI: 10.47248/chp2603010003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Heterogeneity and Plasticity, online erschienen am 28.03.2026. Verfasst von Jingjing Wu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dysregulation of the Hippo signaling pathway, characterized by aberrant activation of the transcriptional coactivators YAP1 and TAZ, drives tumor progression, immunosuppression, and metastasis. Hippo pathway components are emerging therapeutic targets in several solid tumors, however, the expression profiles of Hippo coactivators YAP1, TAZ, and their transcriptional factors TEAD1-4 in gastric cancer peritoneal metastases (GCPMs), and their therapeutic value, are unknown. In this study, we sought to determine the expression status of YAP1, TAZ, and TEAD1-4 in GCPMs and to evaluate whether dual targeting of YAP1 and TAZ provides superior antitumor activity compared with inhibition of either coactivator alone.

Methods

Expression of YAP1, TAZ, and TEAD1–4 was examined in GCPMs by single-cell RNA sequencing and co-immunofluorescent staining. Functional studies using genetic knockout and antisense oligonucleotide (ASO) inhibition of YAP1 or TAZ were performed to assess antineoplastic effects in vitro and in vivo. Co-immunoprecipitation and luciferase reporter assays were used to characterize YAP1/TAZ interactions with TEADs and AP-1 components (JUN and FOSB) and to quantify transcriptional activity. Antitumor efficacy was validated in patient-derived xenograft (PDX) and KP-Luc2 syngeneic models.

Results

YAP1, TAZ, and TEADs1-4 were highly coexpressed in GCPMs and correlated with poor survival. YAP1 inhibition alone elicited compensatory upregulation of TAZ, while combined inhibition of both coactivators maximally repressed cell proliferation and invasion in vitro, and tumor growth in vivo. Increased TAZ complexation with TEAD4 and AP-1 (c-JUN and FOSB) heterodimer was observed following YAP1 knockdown or pharmacological ASO inhibition. Dual inhibition of YAP1 and TAZ was required to maximally suppress YAP1/TAZ expression and reduce their nuclear accumulation, transactivation of TEAD, and activation of downstream genes.

Conclusions

These findings show that combined YAP1 and TAZ inhibition holds promise for the treatment of GCPM, a highly lethal disease with an urgent need for novel treatment options.

Schlagwörter

Stichwörter der Autor:innen

Antisense oligonucleotide (ASO)Hippo pathwayTAZTEAD1-TEAD4YAP1gastric cancer peritoneal metastasis (GCPM)targeted therapy

Autor:innen und Institutionen

  • Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
  • Coriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
  • Camden Cancer Research Center, 403 Haddon Ave, Camden, NJ, 08103, USA.
  • Departments of Biomedical Sciences and Surgery, Cooper Medical School of Rowan University, 401 Broadway, Camden, NJ, 08103, USA.
  • Department of Medicine, Yale School of Medicine and Yale Cancer Center, PO Box 208028, New Haven, CT 06520-8028, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Wu, J., Athavale, D., Balch, C., Zhao, J., Zou, G., Fan, Y., Zhang, Y., Zhao, J., Ghelfi, M., Pompetti, A., Calendo, G., Scott, A., Shao, S., Yao, X., Pizzi, M. P., Vellano, C., Khazak, V., Zhang, S., Yap, T. A., …, & Song, S. (2026). YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis. Cancer Heterogeneity and Plasticity. https://doi.org/10.47248/chp2603010003

Vancouver

Wu J, Athavale D, Balch C, Zhao J, Zou G, Fan Y, et al. YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis. Cancer Heterogeneity and Plasticity. 2026. doi:10.47248/chp2603010003

BibTeX
@article{Wu2026,
  author = {Wu, Jingjing and Athavale, Dipti and Balch, Curt and Zhao, Junsong and Zou, Gengyi and Fan, Yibo and Zhang, Yanting and Zhao, Joseph and Ghelfi, Mikel and Pompetti, Anthony and Calendo, Gennaro and Scott, Ailing and Shao, Shan and Yao, Xiaodan and Pizzi, Melissa Pool and Vellano, Christopher and Khazak, Vladimir and Zhang, Sheng and Yap, Timothy A and Dhar, Shilpa S and Sundar, Raghav and Spitz, Francis and Grana, Generosa and Ajani, Jaffer A and Song, Shumei},
  title = {YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis},
  journal = {Cancer Heterogeneity and Plasticity},
  year = {2026},
  doi = {10.47248/chp2603010003}
}
Kostenlos starten →